Evidence map›Paper›PMID 37072726›Full record

ArticleBMC infectious diseases2023

Survival and predictors of mortality after completion of TB treatment among people living with HIV: a 5-year analytical cohort.

Ivan Lumu, Joseph Musaazi, Aggrey Semeere, Ian Handel, Barbara Castelnuovo

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Ivan LumuInfectious Diseases Institute - College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda. ilumu@idi.co.ug.
Joseph MusaaziInfectious Diseases Institute - College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda.
Aggrey SemeereInfectious Diseases Institute - College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda.
Ian HandelEdinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom.
Barbara CastelnuovoInfectious Diseases Institute - College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda.
Infectious Diseases Institute · UGMakerere University · UGThe Medical Device (United Kingdom) · GBUniversity of Edinburgh · GB

Funding

East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional ConsortiumU01AI069911 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AGGREY SEMWENDERO SEMEERE, Kara Kay Wools-Kaloustian · 2006 to 2026
$57.7M
Uganda-UCSF Research Training in HIV-Associated MalignanciesD43CA153717 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARTIN, JEFFREY N · 2010 to 2013
$1.9M
NCI NIH HHS D43 CA153717NIAID NIH HHS U01 AI069911
6 · The paper itself

Abstract

backgroundAfter completion of TB treatment patients may remain at risk of co-morbidity and mortality. We determined the survival and predictors of all-cause mortality after completing TB treatment among ART-experienced patients.

methodsThis was a retrospective cohort analysis of all ART experienced patients who completed TB treatment at a specialist HIV clinic in Uganda, between 2009 and 2014. The patients were followed for five years after TB treatment. We determined the cumulative probability of death, and predictors of mortality using Kaplan-Meier methods and Cox proportional hazard models, respectively.

resultsA total 1,287 patients completed TB treatment between 2009 and 2014, of which 1,111 were included in the analysis. At TB treatment completion, the median age was 36 years (IQR: 31-42), 563 (50.7%) were males, and median CD4 cell count was 235 cells/mL (IQR: 139-366). The person-time at risk was 4410.60 person-years. The all-cause mortality rate was 15.42 (95% CI: 12.14-19.59) per 1000 person-years. The probability of death at five years was 6.9% (95%CI: 5.5- 8.8). In the multivariable analysis, CD4 count < 200 cells/mL was a predictor of all-cause mortality (aHR = 1.81, 95%CI:1.06-3.11, p = 0.03) alongside history of retreatment (aHR = 2.12, 95%CI: 1.16-3.85, p = 0.01).

conclusionSurvival post TB treatment in ART experienced PLHIV is reasonably good. Most deaths occur within two years after TB treatment completion. Patients with a low CD4 count and those with a history of retreatment have an increased risk of mortality which underscores the need for TB prophylaxis, detailed assessment, and close monitoring after completion of TB treatment.

Indexed as

HIV InfectionsTuberculosisAdultCohort StudiesFemaleHumansMaleProportional Hazards ModelsRetrospective StudiesAntiretroviral therapyHIVSurvivalTB treatment completionTuberculosis

Identifiers

PMID37072726
PMCPMC10111785
OpenAlexW4366281560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.